Shadow of a Stout

The Success of Oncortaget Journal


Oncotarget is a peer-reviewed and open access medical journal based in the United States. The term Oncotarget includes all cellular functions, molecules, and pathways common in cancer and aging, lymphocytes and neurons, atherosclerosis and neurodegeneration, cancer cells, and microbes. It publishes papers online on a weekly basis. Besides, each issue can be printed on demand. It covers research based on all aspects of oncology. It was established in 2010 and is usually published by Impact Journals.

The journal is indexed and abstracted in Index Medicus, BIOSIS Previews, Science Citation Index Expanded, and Scopus. Oncotarget has a mission of ensuring that scientific results are widely and rapidly available, eliminating the border between specialties. It also focuses on maximizing the impact of research through insightful review, linking different fields of biomedical science to foster the application of clinical and basic science to avoid diseases. The journal has also enhanced exceptional discoveries are shared them widely and what Oncotarget knows.

With a leadership of the most prominent scientist, Oncortaget helps researchers contribute to the progress of science. The success of Oncotarget has prompted the launch of other sections beyond oncology such as Neuroscience, Cell biology, pharmacology, metabolism, Cardiology, Endocrinology among others. Its impact factor is at 5.168, with the ResearchGate data. It is based on the average citation counts from work published in the journal. It has enabled people whose journals are mistakenly rejected by leading journals to submit their papers to them with peer reviews sourced from the other journal and a rebuttal letter and more information click here.

Oncortarget will start publishing two issues per week instead of the one issue they were previously published due to increased demand. Oncotarget is giving alt-metric article reports free. They are doing that to provide a real-time tracking of articles in digital and traditional media channels on Facebook before accruing of traditional citations and Oncotarget lacrosse camp.

Oncotarget editors evaluate the manuscripts based on scientific novelty, merit, presentation and quality of data regardless of the authors’ sexual orientation, race, citizenship, and religious beliefs. Information in the manuscript is only disclosed to the authors, reviewers, and members of the editorial board. Therefore, the information is treated with confidentiality. Peer review is usually obligatory and essential as it helps editors make the right decisions, and they comment to the authors so that they improve on their manuscripts and what Oncotarget knows.

More Visit:

Health and Heart, Health News Comments Off on The Success of Oncortaget Journal

Mikhail Blagosklonny: The Passionate Scientist and His Quest on Treating Cancer and Aging


Mikhail Blagosklonny received his Medical Doctorate (M.D.) in general medicine as well as his Doctor of Philosophy in biomedical research plus cardiology from Saint Petersburg State Medical University I.P. Pavlov, a Russian medical University. He was appointed as an Oncology Professor in the year 2009 at the NY-based Roswell Park Cancer Institute.

Mikhail was appointed as an Associate Medicine Professor in 2002, at the NYMC (NY Medical College), in Valhalla, NY before taking a role as the Senior Scientist at the Albany, NY-based Ordway Research Institute.Mikhail held that post until 2009 when he got appointed as a Professor of Oncology, at the NY-based Roswell Park Cancer Institute. The research interests of Mikhail include cancer plus they are targeting cancer therapies protecting normal cells from getting damaged, and the biogerontology (underlying aging mechanisms) and anti-aging drugs and Mikhail’s lacrosse camp.

He is chief editor of Cell Cycle, Oncotarget, and Aging, which as of the year 2013, the journal was ranked the second position in the aging research field. He’s an associate editor of Cancer Biol Ther (Cancer Biology plus Therapy) as well as a member of Cell Death & Differentiation editorial board. Also, he is the founding member of 700forscience, which is a commercialization experts group that helps in creating a system of grassroots support, for innovative biotechnology projects. He has formed a theory about the possible TOR signaling role in aging and cancer as well as recommended using rapamycin, which is a drug that is popular, for cancer as a possible life extension treatment. He’s recognized as one of the impassioned rapamycin advocates in longevity research and what Mikhail knows.

He’s a philanthropist, a professor, a researcher, plus an average person who wants to ensure  that people worldwide receive the best treatment possible regardless of their economic standing. He’s especially interested in medical research field focusing particularly on studying both cancer and aging. Mikhail is mainly interested in the connection between the two and the reason why cancer affects older people more above a certain age. He continues to do research that has and is going to continue to be helpful within the field of Oncology and more information click here.

He is an influential person as a researcher and a professor as well as an expert in his field. Mikhail has been an inspiration to his peers as well as students who want to go on expanding on his research afterward. Mikhail has the goal of finding out a means, not just to treat cancer, but to do it in an efficient way that won’t be painful and costly as the present-day treatments and learn more about Mikhail.

Mikhail has made a lot of progress within his interest field and is hoping that his findings are going to inspire other people all over the world to continue from where he would discontinue because of future studies on He believes that cancer treatment, a deadly and tragic disease, won’t be a treatment that is a luxury in the future for people who are rich or have money; instead, it will be an easy plus a cost-effective treatment.

Cancer Studies, Health and Heart Comments Off on Mikhail Blagosklonny: The Passionate Scientist and His Quest on Treating Cancer and Aging